



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2018-19

Date: 11<sup>th</sup> February, 2019

To,

Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
BSE CODE - 524348  
BSE ID - AARTIDRUGS


National Stock Exchange of India  
Limited  
"Exchange Plaza",  
Bandra - Kurla Complex,  
Bandra(E), Mumbai - 400 051  
NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 11<sup>th</sup> February, 2019 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Monday, 11<sup>th</sup> February, 2019 which commenced at 12 noon and concluded at 2.00 p.m. had *inter-alia* approved the following:

1. The Audited Financial Results (Standalone & Consolidated) for the Quarter & Nine months ended 31<sup>st</sup> December, 2018. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter & Nine months ended 31<sup>st</sup> December, 2018 along with the report of the Statutory Auditors.
2. Re-appointment(s) of Shri Ramdas M. Gandhi, Shri Bhavesh R. Vora, Shri Navin C. Shah, Shri Vilas G. Gaikar, Shri Krishnacharya G. Akamanchi and Smt Priti P. Savla, not liable to retire by rotation and to hold office for a second term as Independent Directors of the Company subject to approval of members by way of Postal Ballot. The adequate disclosures pertaining to the Postal Ballot will be given in due course of time. (The brief profile and details of the Independent Directors re-appointed pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015 is enclosed herewith.)





# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

3. Material Subsidiary Policy pursuant to the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) (Amendment) Regulations, 2018.

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,  
Yours faithfully,  
For Aarti Drugs Limited

*V.S. Ranade*

Vibhav S. Ranade


Company Secretary & Compliance Officer  
ICSI M. No. A35284



Encl: A/A

**Brief profile of re-appointed Independent Directors pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015**

|   |   |  |
|---|---|--|
| Name of the Director  | <b>Shri Ramdas M. Gandhi</b>  | <b>Shri Bhavesh R. Vora</b>  |
| Director Identification Number  | 00029437  | 00267604   |
| Date of Birth & Age   | 14.03.1933 (85 years)   | 13.09.1967 (51 years)  |
| Date of Appointment   | 31.12.2005  | 31.07.2006   |
| Nationality   | Indian  | Indian   |
| Qualifications  | Master's Degree in Law from Mumbai University   | Chartered Accountant   |
| Experience including expertise in functional areas  | He is practising in Mumbai High court for more than 55 years. He is a Corporate lawyer and has extraordinary experience in Commercial law, Corporate law and more. He also serves as Independent Director of Various Listed Companies.  | He is Practising Chartered Accountant with more than 24 years of experience in the field of Stock Broker's, audits, Compliances, derivatives, futures & options, accounting standards and internal management audit. |
| Number of equity shares held in the Company   | 7,730   | NIL  |
| List of Directorships held in other Public  | Aarti Industries Limited<br>Vinyl Chemicals (India) Limited   | Aarti Industries Limited   |
| Chairman/Member of the Committees of the Boards of other public companies in which he is Director | <u><b>Aarti Industries Limited -</b></u><br>Audit Committee - Member<br>Nomination & Remuneration Committee - Chairman<br>Corporate Social Responsibility Committee - Chairman<br><u><b>Vinyl Chemicals (India) Limited</b></u><br>-<br>Audit Committee - Chairman<br>Nomination & Remuneration Committee - Chairman<br>Stakeholder Relationship Committee - Member | <u><b>Aarti Industries Limited -</b></u><br>Audit Committee - Member   |
| Disclosure of Relationships between Director inter-se   | NIL   | NIL  |



**Brief profile of re-appointed Independent Directors pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015**

|  |  |   |
|--|--|---|
| <b>Name of the Director</b>  | <b>Shri Navin C. Shah</b>  | <b>Shri Vilas G. Gaikar</b>   |
| <b>Director Identification Number</b>  | 01415556   | 00033383  |
| <b>Date of Birth &amp; Age</b>   | 22.02.1961 (57 years)  | 28.08.1960 (58 years)   |
| <b>Date of Appointment</b>   | 04.11.2010   | 31.12.2005  |
| <b>Nationality</b>   | Indian   | Indian  |
| <b>Qualifications</b>  | Chartered Accountant   | PHD Technology from Institute of Chemical Technology (ICT)  |
| <b>Experience including expertise in specific functional areas</b>                                       | He is Practicing Chartered Accountant with more than 33 years of experience in the field of Income Tax related matters. He has also expertise in Goods and Service Tax (GST). He has been associated with the Company since the year 2010. | He is presently serving as Vice - Chancellor of Dr. Babasaheb Ambedkar Technological University, Maharashtra. His field of specialization and research includes Process Intensification using Microwave, Light and alternative energy sources, Thermochemical conversions of Biomass, Soft Condensed Matter, Reactive Separations and Design by Molecular Modelling, Clean Technology, Innovation Practices. He is recipient of numerous awards and had published more than 150 publications in referred International Journals. He has been associated with the Company since the year 2005. |
| <b>Number of equity shares held in the Company</b>   | NIL  | NIL   |
| <b>List of Directorships held in other Public Companies</b>  | NIL  | Bharat Oman Refineries Limited  |
| <b>Chairman/Member of the Committees of the Boards of other public companies in which he is Director</b> | NIL  | NIL   |
| <b>Disclosure of Relationships between Director inter-se</b>   | NIL  | NIL   |

V. S. Gaikar  
 22/09/2015

**Brief profile of re-appointed Independent Directors pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015**

|   |  |  |
|---|--|--|
| Name of the Director  | Shri Krishnacharya G. Akamanchi  | Smt. Priti P. Savla  |
| Director Identification Number  | 02354032   | 00662996   |
| Date of Birth & Age   | 01.04.1953 (65 years)  | 13.09.1977 (41 years)  |
| Date of Appointment   | 20.10.2008   | 26.09.2014   |
| Nationality   | Indian   | Indian   |
| Qualifications  | B.SC - (TECH), B.SC - (HONS), PHD -Technology  | Chartered Accountant   |
| Experience including expertise in specific functional areas                                       | He is also Professor of Pharmaceutical Technology at the Institute of Chemical Technology (ICT) [formerly known as University Department of Chemical Technology]. He has more than 100 research publications in reputed International Journals. He has been associated with the Company since the year 2008. | She is a practicing Chartered Accountant and a partner in KPB & Associates, Chartered Accountants firm based in Mumbai & Thane. She is a qualified certificate holder in Entrepreneurs' Development Program from Indian School of Business, Hyderabad. |
| Number of equity shares held in the Company   | NIL  | NIL  |
| List of Directorships held in other Public Companies  | NIL  | Aarti Industries Limited   |
| Chairman/Member of the Committees of the Boards of other public companies in which he is Director | NIL  | <b><u>Aarti Industries Limited -</u></b><br>Audit Committee - Member   |
| Disclosure of Relationships between Director inter-se   | NIL  | NIL  |





# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)  
Fax. : 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

| STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC, 2018 |   |   |                            |                            |                            |   |                            |                            |                            |  |  |  |  |
|---|---|---|----------------------------|----------------------------|----------------------------|---|----------------------------|----------------------------|----------------------------|--|--|--|--|
| (Rs. in lakhs except for share data)  |   |   |                            |                            |                            |   |                            |                            |                            |  |  |  |  |
| Sr. No.   | Particulars   | Standalone                                  |                            |                            |                            | Consolidated                                |                            |                            |                            | Year Ended                               |  |  |  |
|   |   | Quarter Ended<br>30th Sep 2018<br>(Audited) | 31st Dec 2017<br>(Audited) | 31st Dec 2018<br>(Audited) | 31st Dec 2018<br>(Audited) | Quarter Ended<br>30th Sep 2018<br>(Audited) | 31st Dec 2017<br>(Audited) | 31st Dec 2018<br>(Audited) | 31st Dec 2018<br>(Audited) | Year Ended<br>31st Mar 2018<br>(Audited) | Year Ended<br>31st Dec 2017<br>(Audited) | Year Ended<br>31st Dec 2018<br>(Audited) | Year Ended<br>31st Mar 2018<br>(Audited) |
| I   | Revenue from operations   | 35,065                                      | 30,821                     | 1,02,171                   | 84,467                     | 1,15,966                                    | 38,011                     | 34,741                     | 33,541                     | 1,10,181                                 | 93,188                                   | 1,26,257                                 |  |
| II  | Other income  | 21  | 13                         | 125                        | 27                         | 117   | 17                         | 10                         | 13                         | 118                                      | 28                                       | 105                                      |  |
| III   | Total Income (I + II)   | 35,086                                      | 30,834                     | 1,02,296                   | 84,494                     | 1,16,083                                    | 38,027                     | 34,751                     | 33,554                     | 1,10,299                                 | 93,216                                   | 1,26,362                                 |  |
| IV  | Expenses :  |   |                            |                            |                            |   |                            |                            |                            |  |  |  |  |
|   | (a) Cost of materials consumed  | 25,670                                      | 19,014                     | 70,029                     | 53,844                     | 74,565                                      | 27,562                     | 24,354                     | 20,562                     | 75,478                                   | 58,290                                   | 79,777                                   |  |
|   | (b) Purchase of stock-in-trade  | 805   | 660                        | 2,421                      | 1,927                      | 2,597                                       | 1,115                      | 1,110                      | 943                        | 3,166                                    | 3,052                                    | 3,976                                    |  |
|   | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (3,579)                                     | (336)                      | (4,706)                    | (3,974)                    | (5,560)                                     | (3,399)                    | (2,289)                    | (256)                      | (4,796)                                  | (3,737)                                  | (5,487)                                  |  |
|   | (d) Excise duty/taxes on goods sold   | -   | -                          | 1,920                      | 1,920                      | 1,920                                       | -                          | -                          | -                          | -  | 1,894                                    | 1,894                                    |  |
|   | (e) Employee benefits expense   | 1,308                                       | 1,296                      | 3,889                      | 3,721                      | 5,049                                       | 1,486                      | 1,476                      | 1,501                      | 4,447                                    | 4,287                                    | 5,794                                    |  |
|   | (f) Finance costs   | 987   | 844                        | 2,783                      | 2,450                      | 3,301                                       | 1,048                      | 973                        | 906                        | 2,962                                    | 2,603                                    | 3,496                                    |  |
|   | (g) Depreciation and amortisation expense   | 1,024                                       | 940                        | 3,011                      | 2,815                      | 3,780                                       | 1,063                      | 1,072                      | 997                        | 3,175                                    | 2,984                                    | 4,006                                    |  |
|   | (h) Other expenses  | 5,766                                       | 5,102                      | 15,857                     | 14,227                     | 19,211                                      | 6,062                      | 5,390                      | 5,399                      | 16,740                                   | 15,216                                   | 20,456                                   |  |
|   | Total expenses (IV)   | 31,981                                      | 29,295                     | 93,284                     | 76,931                     | 1,04,862                                    | 34,845                     | 32,078                     | 30,051                     | 1,01,172                                 | 84,588                                   | 1,13,911                                 |  |
| V   | Profit before exceptional items and tax (III - IV)                                | 3,105                                       | 3,308                      | 9,011                      | 7,563                      | 11,221                                      | 3,083                      | 2,673                      | 3,503                      | 9,127                                    | 8,628                                    | 12,450                                   |  |
| VI  | Exceptional items   | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
| VII   | Profit before tax (V - VI)  | 3,105                                       | 3,308                      | 9,011                      | 7,563                      | 11,221                                      | 3,083                      | 2,673                      | 3,503                      | 9,127                                    | 8,628                                    | 12,450                                   |  |
| VIII  | Tax Expenses :  |   |                            |                            |                            |   |                            |                            |                            |  |  |  |  |
|   | Provision for taxation - Current  | 740   | 830                        | 2,240                      | 1,900                      | 3,015                                       | 742                        | 701                        | 877                        | 2,272                                    | 2,139                                    | 3,280                                    |  |
|   | - MAT credit entitlement  | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
|   | - Earlier year  | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
|   | Provision for deferred taxation   | 250   | 275                        | 615                        | 600                        | 865   | 252                        | 167                        | 293                        | 625                                      | 658                                      | 940                                      |  |
|   | Total tax expenses (VIII)   | 990   | 1,105                      | 2,855                      | 2,500                      | 3,880                                       | 994                        | 868                        | 1,170                      | 2,896                                    | 2,797                                    | 4,220                                    |  |
| IX  | Profit/(Loss) for the period from continuing operations (VII - VIII)              | 2,115                                       | 2,203                      | 6,156                      | 5,063                      | 7,341                                       | 2,089                      | 1,805                      | 2,333                      | 6,231                                    | 5,831                                    | 8,231                                    |  |
| X   | Profit / (Loss) from discontinuing operations                                     | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
| XI  | Tax expenses of discontinuing operations  | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
| XII   | Profit / (Loss) from discontinuing operations ( X - XI )                          | -   | -                          | -                          | -                          | -   | -                          | -                          | -                          | -  | -  | -  |  |
| XIII  | Profit / (Loss) for the period ( IX - XII )                                       | 2,115                                       | 2,203                      | 6,156                      | 5,063                      | 7,341                                       | 2,089                      | 1,805                      | 2,333                      | 6,231                                    | 5,831                                    | 8,231                                    |  |
| XIV   | Other Comprehensive Income  | -   | -                          | -                          | -                          | (27)  | -                          | -                          | -                          | -  | -  | (27)                                     |  |
| XV  | Total Comprehensive Income for the period (XIII+XIV)                              | 2,115                                       | 2,203                      | 6,156                      | 5,063                      | 7,314                                       | 2,089                      | 1,805                      | 2,333                      | 6,231                                    | 5,831                                    | 8,204                                    |  |
| XVI   | Paid up equity share capital (face value of Rs. 10 each)                          | 2,358                                       | 2,386                      | 2,358                      | 2,386                      | 2,358                                       | 2,358                      | 2,358                      | 2,386                      | 2,358                                    | 2,386                                    | 2,358                                    |  |
| XVII  | Earning per equity share ( in Rs.) (not annualised)                               |   |                            |                            |                            |   |                            |                            |                            |  |  |  |  |
|   | (1) Basic   | 8.97  | 9.23                       | 26.11                      | 21.22                      | 30.67                                       | 8.86                       | 7.65                       | 9.78                       | 26.42                                    | 24.44                                    | 34.41                                    |  |
|   | (2) Diluted   | 8.97  | 9.23                       | 26.11                      | 21.22                      | 30.67                                       | 8.86                       | 7.65                       | 9.78                       | 26.42                                    | 24.44                                    | 34.41                                    |  |

Notes :  
 1 The above results for the quarter and period ended 31st December, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 11th February, 2019.  
 2 Company has only one business segment i.e. pharmaceuticals.  
 3 Figures for the previous Quarter have been regrouped or rearranged wherever necessary.  
 4 The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.



For AARTI DRUGS LIMITED  
 Harshit M. Savla  
 Harshit M. Savla  
 JT. MANAGING DIRECTOR

Place: Mumbai  
 Date: 11th February, 2019

# KIRTANE & PANDIT

## Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To  
The Board of Directors,  
AARTI DRUGS LIMITED.

We have audited the quarterly standalone financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended December 31, 2018 and the year to date financial results for the period from April 1, 2018 to December, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

These standalone quarterly as well as year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date standalone financial results:

- (i) Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5<sup>th</sup> July 2016 in this regard.
- (ii) Give a true and fair view of the net profit and total comprehensive income and other financial information for the quarter ended December 31, 2018 as well as the year to date results for the period from April 1, 2018 to December 31, 2018.

**For KIRTANE & PANDIT LLP**  
Chartered Accountants  
Firm Registration No.: 105215W/W100057

  
CA Milind Bhave  
Partner  
Membership No.: 047973



Place: Mumbai  
Date: 11.02.2019



# KIRTANE & PANDIT

## Auditor's Report on Quarterly Consolidated Financial Results of Aarti Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements, 2015

To,  
The Board of Directors,  
Aarti Drugs Limited.

We have audited accompanying Statement of consolidated financial results of **Aarti Drugs Limited** ("the Company") and its subsidiaries (the Company and its subsidiaries together referred as "the Group") for the quarter ended December 31, 2018 ("the Statement"), being submitted by the Company to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

These quarterly as well as year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain moderate assurance as to whether the Statements are free of material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of risks, of material misstatement of the Statement, whether due to fraud or error. An audit also includes evaluating the appropriateness of the accounting policies used and significant estimates made by management as well as evaluating the overall presentation of the management. We believe that audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

We did not audit the financial statements of the subsidiaries included in the quarterly consolidated financial results, whose interim financial statements reflect total revenue as at quarter end of Rs 109,87,14,395/-. These interim financial statements and other financial information have been audited by the other auditor whose report has been furnished to us, and our opinion on the quarterly financial results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.



Page 1 of 2

Kirtane & Pandit LLP - Chartered Accountants  
Bengaluru | Hyderabad | Mumbai | Nashik | Pune

In our opinion, and to the best of our information and according to the explanations given to us, the Statement

i) includes the results of a subsidiary as given below :

a. Pinnacle Life Science Private Limited


ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016; and

iii) give true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated profit and other comprehensive income for the period and other financial information of the Group for the quarter ended December 31, 2018.

**For KIRTANE & PANDIT LLP**

Chartered Accountants

Firm Registration No.: 105215W/W100057



CA Milind Bhave

Partner

Membership No.: 047973



Place: Mumbai

Date: 11.02.2019